From the Journals

Orthopedic problems in children can be the first indication of acute lymphoblastic leukemia


 

FROM THE JOURNAL OF ORTHOPAEDICS

The diagnosis of acute lymphoblastic leukemia (ALL) can be delayed because of vague presentation and normal hematological results. Orthopedic manifestations may be the primary presentation of ALL to physicians, and such symptoms in children should be cause for suspicion, even in the absence of hematological abnormalities, according to a report published in the Journal of Orthopaedics.

The study retrospectively assessed 250 consecutive ALL patients at a single institution to identify the frequency of ALL cases presented to the orthopedic department and to determine the number of these patients presenting with normal hematological results, according to Amrath Raj BK, MD, and colleagues at the Manipal (India) Academy of Higher Education.

Suspicion warranted

Twenty-two of the 250 patients (8.8%) presented primarily to the orthopedic department (4 with vertebral compression fractures, 12 with joint pain, and 6 with bone pain), but were subsequently diagnosed with ALL. These results were comparable to previous studies. The mean patient age at the first visit was 5.6 years; 13 patients were boys, and 9 were girls. Six of these 22 patients (27.3%) had a normal peripheral blood smear, according to the researchers.

“Acute leukemia should be considered strongly as a differential diagnosis in children with severe osteoporosis and vertebral fractures. Initial orthopedic manifestations are not uncommon, and the primary physician should maintain a high index of suspicion as a peripheral smear is not diagnostic in all patients,” the researchers concluded.

The authors reported that there was no outside funding source and that they had no conflicts.

SOURCE: Raj BK A et al. Journal of Orthopaedics. 2020;22:326-330.

Recommended Reading

Acute lymphoblastic leukemia can be successfully treated in the frail elderly
MDedge Hematology and Oncology
Risk index stratifies pediatric leukemia patients undergoing HSCT
MDedge Hematology and Oncology
Omitting whole body irradiation before HSCT: Trial stopped early
MDedge Hematology and Oncology
HSCT may be best option for therapy-related ALL
MDedge Hematology and Oncology
Inotuzumab / bosutinib treat R/R Ph+ ALL, CML in blast phase
MDedge Hematology and Oncology
Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy
MDedge Hematology and Oncology
Polygenic risk score may predict VTE in adolescents, but not adults, with ALL
MDedge Hematology and Oncology
CSF metabolomic profile linked to cancer-related fatigue in children with ALL
MDedge Hematology and Oncology
TKI choice key for fit/unfit patients with Ph+ALL
MDedge Hematology and Oncology
Survey quantifies COVID-19’s impact on oncology
MDedge Hematology and Oncology